Our assessment of a potential therapeutic effect of muscle PGC-1α in dysferlinopathies, leading to an unexpected outcome, has resulted in the discovery of substantial remodeling of muscle metabolism in mice with an ablated dysferlin gene. This evidence concerns the gene PPARGC1A and neuromuscular disease caused by qualitative or quantitative defects of dysferlin.